KR20230017830A - 비소세포폐암의 치료에 사용하기 위한 egfr tki - Google Patents

비소세포폐암의 치료에 사용하기 위한 egfr tki Download PDF

Info

Publication number
KR20230017830A
KR20230017830A KR1020227045541A KR20227045541A KR20230017830A KR 20230017830 A KR20230017830 A KR 20230017830A KR 1020227045541 A KR1020227045541 A KR 1020227045541A KR 20227045541 A KR20227045541 A KR 20227045541A KR 20230017830 A KR20230017830 A KR 20230017830A
Authority
KR
South Korea
Prior art keywords
egfr
egfr tki
tki
acceptable salt
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227045541A
Other languages
English (en)
Korean (ko)
Inventor
유리 루카젠코브
세르반 기오르규
플라비아 보렐리니
헬렌 만
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20230017830A publication Critical patent/KR20230017830A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227045541A 2020-05-27 2021-05-26 비소세포폐암의 치료에 사용하기 위한 egfr tki Pending KR20230017830A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063030372P 2020-05-27 2020-05-27
US63/030,372 2020-05-27
PCT/EP2021/063992 WO2021239786A1 (en) 2020-05-27 2021-05-26 Egfr tkis for use in the treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
KR20230017830A true KR20230017830A (ko) 2023-02-06

Family

ID=76181131

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045541A Pending KR20230017830A (ko) 2020-05-27 2021-05-26 비소세포폐암의 치료에 사용하기 위한 egfr tki

Country Status (14)

Country Link
US (3) US20210369709A1 (enExample)
EP (1) EP4157267B1 (enExample)
JP (1) JP2023529812A (enExample)
KR (1) KR20230017830A (enExample)
CN (2) CN115776889A (enExample)
AU (1) AU2021279171A1 (enExample)
BR (1) BR112022023519A2 (enExample)
CA (1) CA3183434A1 (enExample)
DK (1) DK4157267T3 (enExample)
FI (1) FI4157267T3 (enExample)
IL (1) IL298216A (enExample)
MX (1) MX2022014903A (enExample)
TW (1) TW202216149A (enExample)
WO (1) WO2021239786A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022526159A (ja) 2019-03-29 2022-05-23 アストラゼネカ・アクチエボラーグ 非小細胞肺がんの治療に使用するためのオシメルチニブ
US12649792B2 (en) 2019-05-06 2026-06-09 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
WO2024118611A2 (en) * 2022-11-28 2024-06-06 Brown University Treatment of epidermal growth factor receptor mutant non-small cell lung cancer
CN117298116A (zh) * 2023-08-08 2023-12-29 江苏晨泰医药科技有限公司 盐酸佐利替尼制剂
CN121177212B (zh) * 2025-11-25 2026-03-03 中南大学湘雅二医院 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
DK3686193T3 (da) * 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
ES3069593T3 (en) 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN105315259B (zh) 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
AU2015360360B2 (en) 2014-12-11 2020-06-25 Beta Pharma (Shanghai) Co., Ltd. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
CN107614503B (zh) 2015-04-29 2020-03-10 广东众生药业股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂
EP3661519A1 (en) * 2017-08-03 2020-06-10 Novartis AG Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor

Also Published As

Publication number Publication date
JP2023529812A (ja) 2023-07-12
CA3183434A1 (en) 2021-12-02
IL298216A (en) 2023-01-01
AU2021279171A1 (en) 2023-02-02
EP4157267A1 (en) 2023-04-05
CN115776889A (zh) 2023-03-10
DK4157267T3 (da) 2026-08-03
US20210369709A1 (en) 2021-12-02
WO2021239786A1 (en) 2021-12-02
US20240423978A1 (en) 2024-12-26
US20250325543A1 (en) 2025-10-23
MX2022014903A (es) 2023-01-04
EP4157267B1 (en) 2026-07-08
CN122376595A (zh) 2026-07-14
TW202216149A (zh) 2022-05-01
FI4157267T3 (fi) 2026-08-12
BR112022023519A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
US20240423978A1 (en) EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER
AU2017329090B9 (en) Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
RU2563193C2 (ru) Комбинации ингибитора pi3k и ингибитора мек
US12465608B2 (en) Osimertinib for use in the treatment of non-small cell lung cancer
JP2025530296A (ja) 転移性癌を治療するためのｐｌｋ１阻害剤と抗血管新生剤の併用
JP2023510426A (ja) 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
WO2023187037A1 (en) Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
AU2019344764B2 (en) Quinoline derivative used for treating small cell lung cancer
US20210161897A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2023531375A (ja) がん治療における使用のためのベルバラフェニブ
EA052374B1 (ru) Осимертиниб для применения в лечении немелкоклеточного рака легкого
HK1175125B (en) Combinations of a pi3k inhibitor and a mek inhibitor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902